Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403371 | 0.85 | SRD5A1 (0.49) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL3506854 | 0.85 | SRD5A1 (0.49) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL3506851 | 0.85 | SRD5A1 (0.49) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL5339929 | 0.83 | AR (0.58) | ARSRD5A2KCNH2 | |
| SCHEMBL5247468 | 0.83 | AR (0.58) | ARSRD5A2KCNH2 | |
| SCHEMBL5212635 | 0.83 | AR (0.66) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL7080792 | 0.83 | AR (0.66) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL5214133 | 0.80 | SRD5A1 (0.67) | ARSRD5A1SRD5A2 | |
| SCHEMBL7076988 | 0.80 | SRD5A1 (0.67) | ARSRD5A1SRD5A2 | |
| SCHEMBL9748321 | 0.80 | AR (0.55) | ARSRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287326-A1 | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators | AR, NR5A1, NR3C1 | AR 1/4885SRD5A1 12/4885SRD5A2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.